Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.
Normally factor (F) VIII is not expressed in megakaryocytes, but when human FVIII was transgenically expressed in murine megakaryocytes, it was stored in platelet alpha-granules and released at sites of injury. This platelet FVIII (pFVIII) is effective in correcting hemostasis, even in the presence of circulating inhibitors, so it offers a potential gene therapy strategy for hemophilia A. To understand clot development by pFVIII, we have examined clot response to laser injury in both cremaster arterioles and venules in FVIII(null) mice either infused with FVIII or transgenic for pFVIII. In both sets of vessels, pFVIII is at least as effective as infused FVIII. However, there are temporal and spatial differences in fibrin and platelet accumulation within clots depending on how FVIII is delivered. These differences may be related to the temporal and spatial distribution of the alpha-granular-released FVIII within the developing clot, and may explain the increased frequency and size of embolic events seen with pFVIII. These observations may not only have implications for the use of pFVIII in gene therapy for hemophilia A, but may also have physiologic consequences, explaining why many procoagulant factors are delivered both in the plasma and in platelet alpha-granules.
Division of Hematology, Children's Hospital of Philadelphia, PA 19104, USA.
Michael
M
Neyman
Jamie
J
Gewirtz
Mortimer
M
Poncz
D000818:Animals; D001777:Blood Coagulation; D001792:Blood Platelets / Q000737:chemistry*; D004195:Disease Models, Animal; D005169:Factor VIII; D005337:Fibrin; D006487:Hemostasis; D006801:Humans; D008533:Megakaryocytes / Q000737:chemistry; D051379:Mice; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D008833:Microcirculation; D013927:Thrombosis
D005169:Factor VIII; D005337:Fibrin